Cargando…

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors

Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune infiltrates and/or an Interferon (IFN) signature indicative of a T-cell-inflamed phenotype. Melanoma and lung cancer demonstrate high response rates to ICIs and are commonly referred to as “hot tumors”. These are...

Descripción completa

Detalles Bibliográficos
Autor principal:	Maleki Vareki, Saman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307306/ https://www.ncbi.nlm.nih.gov/pubmed/30587233 http://dx.doi.org/10.1186/s40425-018-0479-7

Ejemplares similares

The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
por: Aghamajidi, Azin, et al.
Publicado: (2022)

The Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Neither Hot nor Cold
por: Rubin, Samuel J. S., et al.
Publicado: (2022)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
por: Vryza, Paraskevi, et al.
Publicado: (2023)

Hot and cold tumors: Immunological features and the therapeutic strategies
por: Wang, Lianjie, et al.
Publicado: (2023)

Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
por: Ullman, Nicholas A., et al.
Publicado: (2022)

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
por: Kerepesi, Csaba, et al.
Publicado: (2020)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
por: Draganov, Dobrin, et al.
Publicado: (2021)

HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct
por: Evans, Andris M., et al.
Publicado: (2022)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020)

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
por: Hong, Megan M Y, et al.
Publicado: (2022)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis
por: Wan, Linghong, et al.
Publicado: (2020)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

RNA-based vaccines and innate immune activation: Not too hot and not too cold
por: Frederickson, Robert, et al.
Publicado: (2021)

Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors
por: Reil, Katherine A, et al.
Publicado: (2023)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
por: Shinojima, Naoki, et al.
Publicado: (2023)

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
por: Newman, Jenna H., et al.
Publicado: (2020)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
por: Deluce, Jasna, et al.
Publicado: (2022)

mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy
por: Li, Fengqiao, et al.
Publicado: (2023)

Turning cold tumors into hot tumors by improving T-cell infiltration
por: Liu, Yuan-Tong, et al.
Publicado: (2021)

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
por: Rytlewski, Jeff, et al.
Publicado: (2021)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
por: Cortellini, Alessio
Publicado: (2020)

On-demand integrated nano-engager converting cold tumors to hot via increased DNA damage and dual immune checkpoint inhibition
por: Liu, Xiaoqing, et al.
Publicado: (2023)

Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined “Complementary Lethality”
por: Rytelewski, Mateusz, et al.
Publicado: (2013)

Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition
por: Wei, Chen, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
por: Wu, Yongfeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u7cqiknvcrm5tl0lbpmn6jv1fp